Latest Breaking News On - Adrian kemp - Page 1 : comparemela.com

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesDaiichi sankyoSusan galbraithAnn oncKen takeshitaAdrian kempAmerican cancer societyEuropean society for medical oncology congressAnticancer researchCompany secretaryInvestor relations teamLung ambition allianceSapporo medical universityNational cancer instituteWorld health organization

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs chemotherapy in patients with advanced nonsquamous nonsmall cell lung cancer in TROPIONLung01 Phase III trial

Highlevel overall survival OS results from the TROPIONLung01 Phase III trial which previously met the dual primary endpoint of progressionfree survival PFS numerically favoured datopotamab deruxtecan DatoDXd compared to docetaxel in the overall trial population of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC treated with at least one prior line of therapy.

United statesUnited kingdomKen takeshitaAnn oncSusan galbraithAdrian kempDaiichi sankyoSapporo medical universityLung ambition allianceAnticancer researchNational cancer instituteEuropean society for medical oncology congressInvestor relations teamAmerican cancer societyWorld health organizationMedical oncology congress

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future.

United kingdomAdrian kempAmolyt pharmaPascal soriotInvestor relations teamCompany secretaryToday astrazenecaTotal revenueChief executive officerInvestor dayFinancial ambition statementsForward looking statementsRare diseasesSecurities litigation reform act

AstraZeneca sets ambition to deliver 80 billion Total Revenue by 2030 and sustained growth post 2030

Today AstraZeneca revealed its bold ambition to deliver 80 billion in Total Revenue by 2030 up from 45.8 billion in 2023.

United kingdomPascal soriotAdrian kempAmolyt pharmaInvestor relations teamTotal revenueChief executive officerInvestor dayFinancial ambition statementsForward looking statementsRare diseasesSecurities litigation reform actMedia contact

AstraZeneca : plans $1 5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K

a0072p FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesUnited kingdomPascal soriotAdrian kempCommission file numberCompany on social media astrazenecaCompany secretarySecurities exchangeSingapore economic development boardInvestor relations teamForeign issuerSecurities exchange actFile numberCrick avenueRegulationst ruleCheong boon